Home

NICE consultation on kidney cancer drugs

2008-08-07T12:26:00

The National Institute for Health and Clinical Excellence has recommended that bevacizumab, sorafenib, sunitinib and temsirolimus should not be treatment options for advanced or metastatic renal cell carcinoma.

You need to be a subscriber to read more

HSJ

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All HSJ news by sector, topic & region
  • Breaking News announcements
  • App for mobile and offline reading
  • Comment and Daily Insights newsletters
  • Regional roundup newsletters
  • Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant
  • 10 expert briefings every fortnight (Premium only)

Subscribe

to HSJ

Already a subscriber? Sign into your account here